Key clinical point: Adding tesetaxel to capecitabine prolonged progression-free survival in patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Major finding: Progression-free survival was 9.8 months with tesetaxel plus capecitabine and 6.9 months with capecitabine monotherapy (hazard ratio, 0.716; P = .003).

Study details: The phase 3 CONTESSA trial included 685 patients previously treated with a taxane.

Disclosures: Odonate Therapeutics sponsored the trial. Study authors disclosed financial relationships with multiple pharmaceutical companies, including the study sponsor.